Use of thermal treatment with CaCl2 and CaO to remove 137Cs in the soil collected from the area near the Fukushima Daiichi Nuclear Power Plant.

A massive amount of soils and inflammable materials of plants etc. contaminated by radiocesium are generated from decontamination work in the Fukushima Daiichi Nuclear Power Plant (FDNPP) accident affected area. In present study, the removal experiments of 137Cs in a soil collected from the FDNPP accident affected area were carried out in a lab-scale electrical heating horizontal furnace through thermal treatment with CaCl2 addition over a temperature of 900 - 1300 °C. The results indicated that the average radioactive concentration of 137Cs in the soil was 52.8 Bq/g. The removal ratio of 137Cs in the soil treated at 1300 °C was 96.3 % when 20 % CaCl2 was added. The addition of CaCl2 and CaO mixture exhibited a synergistic effect on the removal of 137Cs, relative to the addition of CaCl2 alone. Accordingly, the addition of CaCl2 or its mixture with CaO during thermal treatment is suggested to remove 137Cs in the soil collected from the FDNPP accident affected area. Additionally, segregation of the soil sample to fine and coarse fraction and then treated individually are also recommended.

Selective Fabrication of Nanowires with High Aspect Ratios Using a Diffusion Mixing Reaction System for Applications in Temperature Sensing.

The selective fabrication of highly ordered nanowires with high aspect ratios was of low reproducibility, which remains a challenge for laboratory research. In this paper, we report a novel approach for selective fabrication of conductive nanowires on a solid surface via diffusion mixing reaction system formed by a chemical pen. The nanoscale-mixing region was achieved by appropriately adjusting the viscosity of the solution and other parameters with the aid of dyes functioned as a flow boundary indicator. Finite element simulations and analysis were performed to understand the generation of mixing regions and guide the improvement of the chemical pen design. Under the optimal parameters, high aspect ratio silver nanowires (aspect ratio ≈ 1800) were obtained. Silver nanowire arrays with uniform width, gradient width and complex patterns were successfully fabricated. The theoretical value of the temperature coefficient of resistance (TCR) for silver was 0.0038 Ω/°C. A single silver wire temperature sensor with 7-fold increase in temperature coefficient resistance (0.0261 Ω/°C) was fabricated to show the advantages of the chemical pen in the fabrication of nanosensors. With the freedom of the region, simple operability and applicability, the chemical pen was expected to a potential and advanced method for selective nanomodification and processing on subcellular interfaces.

Feline coronavirus antibody titer in cerebrospinal fluid from cats with neurological signs.

To investigate the utility of cerebrospinal fluid (CSF) anti-feline coronavirus (FCoV) antibody test for diagnosis of feline infectious peritonitis (FIP), the antibody titers were tested in CSF and sera from 271 FIP-suspected neurological cats. CSF antibody was detected in 28 cats, which were divided into 2 groups; 15 with CSF titer of 1:80 or lower and 13 with CSF titer of 1:640 or higher. In the latter group, reciprocal serum titer/reciprocal CSF titer was 8 or lower, which is extremely lower than normal range (256-2048), and FCoV RNA was detected in all of 11 CSF samples assayed by RT-PCR. Our findings indicate that CSF titer of 1:640 or higher may be served as a candidate for the index for diagnosing FIP.

Elaborately programmed nanowires fabricated using a tapered push-pull nozzle system.

Elaborately programmed silver nanowire arrays can be prepared using a tapered push-pull nozzle system (TPPNS), which is used to directly write micro-nano wires on a substrate via a two-reagent reaction in the diffusion mixing region. The wires could be precisely positioned on the substrate and their width could be freely controlled from the micro to the nano scale, indicating an advance in the methodologies of controlling and fabricating nanowires. The as-prepared silver three-electrode device can serve as a three-electrode sensor.

Vaporization Mechanisms of Water-Insoluble Cs in Ash During Thermal Treatment with Calcium Chloride Addition.

The vaporization mechanisms of water-insoluble Cs in raw ash and Cs-doped ash during thermal treatment with CaCl2 addition was systematically examined in a lab-scale electrical heating furnace over a temperature range of 500-1500 °C. The results indicate that the water-insoluble Cs in the ash was associated with aluminosilicate as pollucite. Addition of 10% CaCl2 caused the maximum vaporization ratio of Cs in the raw ash to reach approximately 80% at temperatures higher than 1200 °C, whereas approximately 95% of Cs was vaporized at temperatures higher than 1300 °C when 30% CaCl2 was added. The formation of an intermediate compound, CsCaCl3, through the chemical reaction of Cs with CaCl2 was responsible for Cs vaporization by means of the subsequent decomposition of this intermediate upon the increase in temperature. The indirect chlorination of Cs by the gaseous chlorine released from the decomposition of CaCl2 was insignificant. A high CaCl2 content in the resulting annealed products with 30% CaCl2 addition delayed the decomposition of CsCaCl3 and thus lowered the Cs vaporization ratio compared to that with 10% CaCl2 addition at 900-1250 °C. Thermal treatment with CaCl2 addition is a proposed method to remove Cs from Cs-contaminated incineration ash.

Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension.

This randomized, double-blind, placebo-controlled study evaluated the early effects of canagliflozin on blood pressure (BP) in patients with type 2 diabetes mellitus (T2DM) and hypertension. Patients were randomized to canagliflozin 300 mg, canagliflozin 100 mg, or placebo for 6 weeks and underwent 24-hour ambulatory BP monitoring before randomization, on day 1 of treatment, and after 6 weeks. The primary endpoint was change in mean 24-hour systolic BP (SBP) from baseline to week 6. Overall, 169 patients were included (mean age, 58.6 years; glycated hemoglobin, 8.1%; seated BP 138.5/82.7 mm Hg). At week 6, canagliflozin 300 mg provided greater reductions in mean 24-hour SBP than placebo (least squares mean -6.2 vs -1.2 mm Hg, respectively; P=.006). Numerical reductions in SBP were observed with canagliflozin 100 mg. Canagliflozin was generally well tolerated, with side effects similar to those reported in previous studies. These results suggest that canagliflozin rapidly reduces BP in patients with T2DM and hypertension.

[Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].

Two multiple myeloma (MM) patients developed venous thromboembolism (VTE) while being treated with lenalidomide and low-dose dexamethasone. Aspirin is recommended for VTE prophylaxis when using lenalidomide/dexamethasone for MM patients with a standard risk of VTE. Despite aspirin administration, however, these two patients experienced VTE. Following VTE development, warfarin and then a Factor Xa inhibitor, edoxaban, were administered. The edoxaban treatment, especially, resulted in favorable and effective control of VTE. Considering these observations, Factor Xa inhibitors may in future become a preferred option for prevention and treatment of VTE when managing MM patients.

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.

OBJECTIVE: To evaluate the efficacy and safety of canagliflozin, a sodium glucose cotransporter 2 inhibitor, compared with sitagliptin in subjects with type 2 diabetes inadequately controlled with metformin plus sulfonylurea. RESEARCH DESIGN AND METHODS: In this 52-week, randomized, double-blind, active-controlled, phase 3 study, subjects using stable metformin plus sulfonylurea (N = 755) received canagliflozin 300 mg or sitagliptin 100 mg daily. Primary end point was change from baseline in A1C at 52 weeks. Secondary end points included change in fasting plasma glucose (FPG) and systolic blood pressure (BP), and percent change in body weight, triglycerides, and HDL cholesterol. Safety was assessed based on adverse event (AE) reports. RESULTS: At 52 weeks, canagliflozin 300 mg demonstrated noninferiority and, in a subsequent assessment, showed superiority to sitagliptin 100 mg in reducing A1C (-1.03% [-11.3 mmol/mol] and -0.66% [-7.2 mmol/mol], respectively; least squares mean difference between groups, -0.37% [95% CI, -0.50 to -0.25] or -4.0 mmol/mol [-5.5 to -2.7]). Greater reductions in FPG, body weight, and systolic BP were observed with canagliflozin versus sitagliptin (P < 0.001). Overall AE rates were similar with canagliflozin (76.7%) and sitagliptin (77.5%); incidence of serious AEs and AE-related discontinuations was low for both groups. Higher incidences of genital mycotic infections and osmotic diuresis-related AEs were observed with canagliflozin, which led to one discontinuation. Hypoglycemia rates were similar in both groups. CONCLUSIONS: Findings suggest that canagliflozin may be a new therapeutic tool providing better improvement in glycemic control and body weight reduction than sitagliptin, but with increased genital infections in subjects with type 2 diabetes using metformin plus sulfonylurea.